Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. MRK and Daiichi Sankyo's patritumab deruxtecan shows ...

On Saturday, NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with Merck & Co Inc's (NYSE ... Department of the Nasdaq ...

On Saturday, NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with Merck & Co Inc's (NYSE ... Department of the Nasdaq ...

More than 39 million people around the world could die from antibiotic-resistant infections over the next 25 years, according to a study published in The Lancet.  The new study by the Global Research ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

The stock's fall snapped a five-day winning streak.

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $117.96 which represents a slight increase of $2.10 or 1.81% from the prior close of $115.86. The stock opened at $115.8 and touched a ...

Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its ...

Merck (MRK) ended the recent trading session at $117.17, demonstrating a -0.05% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.19%.

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...